81 - Challenging Consults in Clinical Mycology

Monday, October 20, 2025

3:15 PM - 4:30 PM US ET

Location: B405-B407

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

GT

George Thompson, III, MD

Professor
Internal Medicine, Division of Infectious Diseases
University of California Davis Medical Center
Sacramento, CA, United States
Jessica Little, MD (she/her/hers)

Transplant Infectious Diseases Physician
Brigham and Women's Hospital
Boston, MA, United States

Faculty(s)

Andy Miller, MD (he/him/his)

Associate Professor of Clinical Medicine
Infectious Diseases
Hospital for Special Surgery
New York, NY, United States
Peter Pappas, MD

Professor of Medicine
Medicine
University of Alabama at Birmingham
Birmingham, AL, United States
TW

Thomas Walsh, MD, PhD (Hon), FIDSA, FAAM, FECMM

Founding Director
Center for Innovative Therapeutics and Diagnostics (citdx.org)
Richmond, VA, United States

Disclosure(s):

George R. Thompson, MD, III: Astellas Pharma Inc.: Advisor/Consultant, Grant/Research Support; Basilea Pharmaceutica: Advisor/Consultant, Grant/Research Support; Elion Therapeutics: Advisor/Consultant; F2G Limited: Advisor/Consultant, Grant/Research Support; GSK/ViiV Healthcare: Advisor/Consultant, Grant/Research Support; Pfizer, Inc.: Advisor/Consultant; Scynexis Inc.: Advisor/Consultant, Grant/Research Support

Jessica S. Little, MD: Merck and Company, Inc.: Grant/Research Support; Moderna, Inc.: Grant/Research Support

Andy O. Miller, MD: Eli Lilly & Co.: Stocks/Bonds (Private Company)

Peter G. Pappas, MD: Basilea Pharmaceutica: Advisor/Consultant, Grant/Research Support; Melinta Therapuetics: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain the approach to fungal meningitis;
describe indications for testing and approach to treatment for chronic mucocutaneous candidiasis;
describe the approach to fungal bone and joint infections.

Presentations:

3:15 PM - 3:40 PM US ET

Fungal Meningitis
Speaker: Thomas J. Walsh, MD, PhD (Hon), FIDSA, FAAM, FECMM – Center for Innovative Therapeutics and Diagnostics (citdx.org)
3:40 PM - 4:05 PM US ET

Chronic Mucocutaneous Candidiasis: Underlying Diagnoses and Treatment
Speaker: Peter G. Pappas, MD – University of Alabama at Birmingham
4:05 PM - 4:30 PM US ET

Fungal Bone and Joint Infections
Speaker: Andy O. Miller, MD (he/him/his) – Hospital for Special Surgery